EdgeMarket › What Boxer Capital Management, Llc reported owning
What Boxer Capital Management, Llc reported owning
As filed on Form 13F for the quarter ending 2026-03-31, up to 45 days after that date. Long-only US-listed equity — shorts, bonds, cash and non-US listings are not on the form, so this is one leg of the book, not the book.
Reported value
761.7MPositions
54Quarter
2026-03-31Shown below
50largest by value
| holding | value | % of book | shares | price | 1y |
|---|---|---|---|---|---|
| TNGX Tango Therapeutics, Inc. | 227.5M | 29.9% | 10.9M | 23.88 | +253.8% |
| KOD Kodiak Sciences Inc. | 51.9M | 6.8% | 1.4M | 38.33 | +303.5% |
| RVMD Revolution Medicines, Inc. | 48.6M | 6.4% | 500.0K | 209.46 | +479.3% |
| KYMR Kymera Therapeutics, Inc. | 27.4M | 3.6% | 329.1K | 119.80 | +182.9% |
| CELC Celcuity Inc. | 25.7M | 3.4% | 225.0K | 93.53 | +91.8% |
| SRZN Surrozen, Inc./DE | 22.3M | 2.9% | 766.3K | 23.99 | +108.6% |
| ABVX Abivax S.A. | 22.3M | 2.9% | 200.0K | 114.95 | +59.9% |
| unmapped CUSIP 880881107 | 19.8M | 2.6% | 375.0K | — | — |
| PCVX Vaxcyte, Inc. | 18.9M | 2.5% | 325.0K | 62.62 | +100.3% |
| CAPR CAPRICOR THERAPEUTICS, INC. | 17.9M | 2.4% | 590.0K | 6.29 | -12.3% |
| PTGX Protagonist Therapeutics, Inc | 17.9M | 2.4% | 170.0K | 154.32 | +174.4% |
| VIR Vir Biotechnology, Inc. | 16.7M | 2.2% | 1.9M | 9.78 | +124.3% |
| CRVS Corvus Pharmaceuticals, Inc. | 16.1M | 2.1% | 1.1M | 14.46 | +178.6% |
| PRAX Praxis Precision Medicines, Inc. | 15.0M | 2.0% | 46.5K | 375.94 | +730.8% |
| PTCT PTC THERAPEUTICS, INC. | 13.6M | 1.8% | 200.0K | 69.82 | +42.9% |
| PGEN PRECIGEN, INC. | 13.5M | 1.8% | 3.5M | 7.20 | +124.3% |
| DFTX Definium Therapeutics, Inc. | 11.3M | 1.5% | 598.5K | 44.91 | +375.2% |
| AMLX Amylyx Pharmaceuticals, Inc. | 11.1M | 1.5% | 800.0K | 38.66 | +381.4% |
| QURE uniQure N.V. | 10.8M | 1.4% | 662.0K | 48.37 | +212.5% |
| IRD Opus Genetics, Inc. | 10.2M | 1.3% | 2.2M | 4.05 | +249.1% |
| CORT CORCEPT THERAPEUTICS INC | 10.1M | 1.3% | 250.0K | 122.25 | +73.7% |
| URGN UroGen Pharma Ltd. | 9.0M | 1.2% | 500.0K | 46.86 | +142.7% |
| REPL Replimune Group, Inc. | 9.0M | 1.2% | 1.2M | 14.77 | +181.3% |
| COGT Cogent Biosciences, Inc. | 8.7M | 1.1% | 225.0K | 36.73 | +209.6% |
| PALI PALISADE BIO, INC. | 8.4M | 1.1% | 4.8M | 2.10 | +191.7% |
| CBIO CRESCENT BIOPHARMA, INC. | 8.3M | 1.1% | 453.7K | 17.15 | +24.3% |
| unmapped CUSIP 834203309 | 6.7M | 0.9% | 200.0K | — | — |
| ALLO Allogene Therapeutics, Inc. | 6.6M | 0.9% | 2.7M | 2.09 | +97.2% |
| CYTK CYTOKINETICS INC | 6.6M | 0.9% | 100.0K | 76.84 | +105.9% |
| CTNM Contineum Therapeutics, Inc. | 6.5M | 0.8% | 494.0K | 17.19 | +93.8% |
| APGE Apogee Therapeutics, Inc. | 5.9M | 0.8% | 70.0K | 134.75 | +274.1% |
| RLMD RELMADA THERAPEUTICS, INC. | 5.9M | 0.8% | 842.1K | 4.63 | +655.9% |
| ZURA Zura Bio Ltd | 5.4M | 0.7% | 900.0K | 5.85 | +234.3% |
| MLTX MoonLake Immunotherapeutics | 5.1M | 0.7% | 275.0K | 15.76 | -70.9% |
| AVTX Avalo Therapeutics, Inc. | 4.5M | 0.6% | 300.0K | 19.83 | +115.1% |
| INO INOVIO PHARMACEUTICALS, INC. | 4.1M | 0.5% | 2.4M | 1.18 | -36.2% |
| GPCR Structure Therapeutics Inc. | 3.6M | 0.5% | 75.0K | 49.09 | +164.4% |
| SRPT Sarepta Therapeutics, Inc. | 3.3M | 0.4% | 150.0K | 18.79 | -8.7% |
| HELP CYBIN INC. | 3.1M | 0.4% | 640.0K | 12.59 | +90.8% |
| OCUL OCULAR THERAPEUTIX, INC | 3.0M | 0.4% | 350.0K | 11.08 | -7.4% |
| ANTX AN2 Therapeutics, Inc. | 2.6M | 0.3% | 749.0K | 5.81 | +418.8% |
| CLNN Clene Inc. | 2.4M | 0.3% | 477.5K | 4.32 | -23.1% |
| ORIC Oric Pharmaceuticals, Inc. | 2.2M | 0.3% | 176.5K | 14.20 | +49.3% |
| SLDB Solid Biosciences Inc. | 2.2M | 0.3% | 300.0K | 9.30 | +64.3% |
| IVVD Invivyd, Inc. | 1.9M | 0.3% | 1.5M | 1.00 | +57.2% |
| LBRX LB PHARMACEUTICALS INC | 1.7M | 0.2% | 70.0K | 47.62 | — |
| KPTI Karyopharm Therapeutics Inc. | 1.7M | 0.2% | 302.5K | 1.96 | -69.8% |
| NRIX Nurix Therapeutics, Inc. | 1.6M | 0.2% | 100.0K | 26.72 | +180.4% |
| UPB Upstream Bio, Inc. | 1.4M | 0.2% | 150.0K | 6.97 | -57.4% |
| MIST Milestone Pharmaceuticals Inc. | 793.3K | 0.1% | 666.7K | 1.05 | -35.7% |
A position that grew quarter on quarter may simply reflect a higher price: if the stock rose 40% and the manager did nothing, the reported value rose 40%. Reading that as accumulation is reading the price back to yourself. More on that →
The whole archive is one click away.
Screener, filings, insider flow, backtests and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →